{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T05:29:31Z","timestamp":1680586171416},"reference-count":45,"publisher":"SMW Supporting Association","issue":"3","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>AIMS OF THE STUDY: Acquired haemophilia A is a rare disease with an annual incidence of 1.48 per million. Based on clinical observations, we suspect a higher incidence in southern Switzerland, and aimed at providing local epidemiological data, and clinical information regarding diagnosis, treatment and outcome in our region.&#x0D;\nMETHODS: All adult patients with acquired haemophilia A treated between 2013 and 2019 in our facility were included in the present retrospective analysis.&#x0D;\nRESULTS: We treated 11 patients with acquired haemophilia A between 2013 and 2019, resulting in an annual incidence of 4.5 per million (95% confidence interval [CI] 0\u20139.0). Median delay from first symptoms to diagnosis was 4.5 days, and the median age at diagnosis was 79 years (range 23\u201387). Possible causative conditions were: pregnancy (n = 1), polyarteritis nodosa (n = 1), myelodysplastic syndrome (n = 1), chronic human immunodeficiency virus (HIV) (n = 1), and HIV postexposure prophylaxis (n = 1). In five patients no underlying or associated condition was identified. Median activated partial thromboplastin time (aPTT)) at baseline was 79 seconds (65\u2013117; ref. value &lt;38 sec), and FVIII:C 2.15% (&lt;1\u20133.75%). A FVIII:C &lt;1% was present in 4\/10 patients. Median FVIII-inhibitor titre was 10.3 BU\/ml (2.4\u201375.0 BU\/ml). All patients had bleeding symptoms, 5\/10 patients had major bleedings, and 7\/10 patients were treated with bypassing agents. All patients received corticosteroids; 7\/10 patients received immunosuppressive combination therapy. FVIII levels of \u226550% were achieved after a median of 40 days (8\u201362). One patient had a severe immunosuppressive therapy-related infection. An 87-years-old woman died for reasons not related to acquired haemophilia A or immunosuppressive therapy.&#x0D;\nCONCLUSIONS: Acquired haemophilia A is a rare disease, but manageable despite the advanced patient age and comorbidities. Its incidence in Southern Switzerland is higher than previously suspected.<\/jats:p>","DOI":"10.57187\/smw.2023.40048","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T15:36:06Z","timestamp":1680536166000},"page":"40048","source":"Crossref","is-referenced-by-count":0,"title":["Acquired haemophilia A in southern Switzerland from 2013 to 2019: a case series"],"prefix":"10.57187","volume":"153","author":[{"given":"Andrea","family":"Ruberti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna A.","family":"Kremer Hovinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Vettese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Galfetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Monotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamella","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Regazzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Valente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Stussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36756","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"81554","doi-asserted-by":"crossref","unstructured":"Collins PW , Hirsch S , Baglin TP , Dolan G , Hanley J , Makris M , et al.; UK Haemophilia Centre Doctors\u2019 Organisation . Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation. Blood. 2007 Mar;109(5):1870\u20137. https:\/\/doi.org\/10.1182\/blood-2006-06-029850","DOI":"10.1182\/blood-2006-06-029850"},{"key":"81555","doi-asserted-by":"crossref","unstructured":"Borg JY , Guillet B , Le Cam-Duchez V , Goudemand J , L\u00e9vesque H , Group SS ; SACHA Study Group . Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l\u2019H\u00e9mophilie Acquise) registry. Haemophilia. 2013 Jul;19(4):564\u201370. https:\/\/doi.org\/10.1111\/hae.12138","DOI":"10.1111\/hae.12138"},{"key":"81556","doi-asserted-by":"crossref","unstructured":"Green D , Lechner K . A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981 Jun;45(3):200\u20133. https:\/\/doi.org\/10.1055\/s-0038-1650169","DOI":"10.1055\/s-0038-1650169"},{"key":"81557","doi-asserted-by":"crossref","unstructured":"Knoebl P , Marco P , Baudo F , Collins P , Huth-K\u00fchne A , Nemes L , et al.; EACH2 Registry Contributors . Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012 Apr;10(4):622\u201331. https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04654.x","DOI":"10.1111\/j.1538-7836.2012.04654.x"},{"key":"81558","doi-asserted-by":"crossref","unstructured":"Tiede A , Klamroth R , Scharf RE , Trappe RU , Holstein K , Huth-K\u00fchne A , et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study. Blood. 2015 Feb;125(7):1091\u20137. https:\/\/doi.org\/10.1182\/blood-2014-07-587089","DOI":"10.1182\/blood-2014-07-587089"},{"key":"81559","doi-asserted-by":"crossref","unstructured":"Delgado J , Jimenez-Yuste V , Hernandez-Navarro F , Villar A . Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003 Apr;121(1):21\u201335. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04162.x","DOI":"10.1046\/j.1365-2141.2003.04162.x"},{"key":"81560","doi-asserted-by":"crossref","unstructured":"Tengborn L , Baudo F , Huth-K\u00fchne A , Knoebl P , L\u00e9vesque H , Marco P , et al.; EACH2 registry contributors . Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG. 2012 Nov;119(12):1529\u201337. https:\/\/doi.org\/10.1111\/j.1471-0528.2012.03469.x","DOI":"10.1111\/j.1471-0528.2012.03469.x"},{"key":"81561","doi-asserted-by":"crossref","unstructured":"Tiede A , Collins P , Knoebl P , Teitel J , Kessler C , Shima M , et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020 Jul;105(7):1791\u2013801. https:\/\/doi.org\/10.3324\/haematol.2019.230771","DOI":"10.3324\/haematol.2019.230771"},{"key":"81562","doi-asserted-by":"crossref","unstructured":"Lapalud P , Ali T , Cayzac C , Mathieu-Dupas E , Levesque H , Pfeiffer C , et al. The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII. J Thromb Haemost. 2012 Sep;10(9):1814\u201322. https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04850.x","DOI":"10.1111\/j.1538-7836.2012.04850.x"},{"key":"81563","doi-asserted-by":"crossref","unstructured":"Reding MT . Immunological aspects of inhibitor development. Haemophilia. 2006 Dec;12(s6 Suppl 6):30\u20135. https:\/\/doi.org\/10.1111\/j.1365-2516.2006.01363.x","DOI":"10.1111\/j.1365-2516.2006.01363.x"},{"key":"81564","doi-asserted-by":"crossref","unstructured":"Tiede A , Zieger B , Lisman T . Acquired bleeding disorders. Haemophilia. 2021 Feb;27(S3 Suppl 3):5\u201313. https:\/\/doi.org\/10.1111\/hae.14033","DOI":"10.1111\/hae.14033"},{"key":"81565","doi-asserted-by":"crossref","unstructured":"Oldenburg J , Zeitler H , Pavlova A . Genetic markers in acquired haemophilia. Haemophilia. 2010 May;16 Suppl 3:41\u20135. https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02259.x","DOI":"10.1111\/j.1365-2516.2010.02259.x"},{"key":"81566","doi-asserted-by":"crossref","unstructured":"Tiede A , Eisert R , Czwalinna A , Miesbach W , Scharrer I , Ganser A . Acquired haemophilia caused by non-haemophilic factor VIII gene variants. Ann Hematol. 2010 Jun;89(6):607\u201312. https:\/\/doi.org\/10.1007\/s00277-009-0887-3","DOI":"10.1007\/s00277-009-0887-3"},{"key":"81567","doi-asserted-by":"crossref","unstructured":"Kahle J , Orlowski A , Stichel D , Healey JF , Parker ET , Jacquemin M , et al. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. Blood. 2017 Aug;130(6):808\u201316. https:\/\/doi.org\/10.1182\/blood-2016-11-751347","DOI":"10.1182\/blood-2016-11-751347"},{"key":"81568","doi-asserted-by":"crossref","unstructured":"Tiede A , Hofbauer CJ , Werwitzke S , Kn\u00f6bl P , Gottstein S , Scharf RE , et al. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01\/2010 study. Blood. 2016 May;127(19):2289\u201397. https:\/\/doi.org\/10.1182\/blood-2015-09-672774","DOI":"10.1182\/blood-2015-09-672774"},{"key":"81569","doi-asserted-by":"crossref","unstructured":"Kessler CM , Ma AD , Al-Mondhiry HA , Gut RZ , Cooper DL . Assessment of acquired hemophilia patient demographics in the United States: the Hemostasis and Thrombosis Research Society Registry. Blood Coagul Fibrinolysis. 2016 Oct;27(7):761\u20139. https:\/\/doi.org\/10.1097\/MBC.0000000000000582","DOI":"10.1097\/MBC.0000000000000582"},{"key":"81570","doi-asserted-by":"crossref","unstructured":"Hirsiger JR , Martinez M , Tsakiris DA , Cittone MG , Graf L , Oldenburg J , et al. Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID-19 vaccines. J Thromb Haemost. 2022 Apr;20(4):1015\u20138. https:\/\/doi.org\/10.1111\/jth.15665","DOI":"10.1111\/jth.15665"},{"key":"81571","doi-asserted-by":"crossref","unstructured":"Cittone MG , Battegay R , Condoluci A , Terzi di Bergamo L , Fernandes E , Galfetti E , et al. The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccination. J Thromb Haemost. 2021 Sep;19(9):2360\u20132. https:\/\/doi.org\/10.1111\/jth.15421","DOI":"10.1111\/jth.15421"},{"key":"81572","doi-asserted-by":"crossref","unstructured":"Sanges S , Jeanpierre E , Lopez B , Russick J , Delignat S , Carpentier B , et al. Acquired Hemophilia A in IgG4-Related Disease: Case Report, Immunopathogenic Study, and Review of the Literature. Front Immunol. 2020 Dec;11:558811. https:\/\/doi.org\/10.3389\/fimmu.2020.558811","DOI":"10.3389\/fimmu.2020.558811"},{"key":"81573","doi-asserted-by":"crossref","unstructured":"Mizrahi T , Doyon K , Dub\u00e9 E , Bonnefoy A , Warner M , Cloutier S , et al. Relapse pattern and long-term outcomes in subjects with acquired haemophilia A. Haemophilia. 2019 Mar;25(2):252\u20137. https:\/\/doi.org\/10.1111\/hae.13685","DOI":"10.1111\/hae.13685"},{"key":"81574","doi-asserted-by":"crossref","unstructured":"Tiede A , Giangrande P , Teitel J , Amano K , Benson G , Nemes L , et al. Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement. Haemophilia. 2019 Nov;25(6):969\u201378. https:\/\/doi.org\/10.1111\/hae.13844","DOI":"10.1111\/hae.13844"},{"key":"81575","doi-asserted-by":"crossref","unstructured":"Matsumoto T , Nogami K , Ogiwara K , Shima M . A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies. Thromb Haemost. 2012 Feb;107(2):288\u2013301. https:\/\/doi.org\/10.1160\/TH11-05-0331","DOI":"10.1160\/TH11-05-0331"},{"key":"81576","doi-asserted-by":"crossref","unstructured":"Lossing TS , Kasper CK , Feinstein DI . Detection of factor VIII inhibitors with the partial thromboplastin time. Blood. 1977 May;49(5):793\u20137. https:\/\/doi.org\/10.1182\/blood.V49.5.793.793","DOI":"10.1182\/blood.V49.5.793.793"},{"key":"81577","doi-asserted-by":"crossref","unstructured":"Rosner E , Pauzner R , Lusky A , Modan M , Many A . Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost. 1987 Apr;57(2):144\u20137. https:\/\/doi.org\/10.1055\/s-0038-1651083","DOI":"10.1055\/s-0038-1651083"},{"key":"81578","doi-asserted-by":"crossref","unstructured":"Kumano O , Ieko M , Naito S , Yoshida M , Takahashi N , Suzuki T , et al. New formulas for mixing test to discriminate between lupus anticoagulant and acquired hemophilia A. Thromb Res. 2016 Jul;143:53\u20137. https:\/\/doi.org\/10.1016\/j.thromres.2016.05.004","DOI":"10.1016\/j.thromres.2016.05.004"},{"key":"81579","doi-asserted-by":"crossref","unstructured":"Rasmussen KL , Philips M , Tripodi A , Goetze JP . Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review. Eur J Haematol. 2020 Jun;104(6):519\u201325. https:\/\/doi.org\/10.1111\/ejh.13394","DOI":"10.1111\/ejh.13394"},{"key":"81580","doi-asserted-by":"crossref","unstructured":"Lottenberg R , Kentro TB , Kitchens CS . Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med. 1987 Jun;147(6):1077\u201381. https:\/\/doi.org\/10.1001\/archinte.1987.00370060073014","DOI":"10.1001\/archinte.147.6.1077"},{"key":"81581","doi-asserted-by":"crossref","unstructured":"Schulman S , Kearon C ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"81582","doi-asserted-by":"crossref","unstructured":"Tiede A , Wahler S . The rising incidence of acquired haemophilia A in Germany. Haemophilia. 2020.","DOI":"10.1111\/hae.14149"},{"key":"81583","doi-asserted-by":"crossref","unstructured":"Christensen LD , Reilev M , Juul-Larsen HG , J\u00f8rgensen LM , Kaae S , Andersen O , et al. Use of prescription drugs in the older adult population-a nationwide pharmacoepidemiological study. Eur J Clin Pharmacol. 2019 Aug;75(8):1125\u201333. https:\/\/doi.org\/10.1007\/s00228-019-02669-2","DOI":"10.1007\/s00228-019-02669-2"},{"key":"81584","doi-asserted-by":"crossref","unstructured":"Saeedi P , Petersohn I , Salpea P , Malanda B , Karuranga S , Unwin N , et al.; IDF Diabetes Atlas Committee . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. https:\/\/doi.org\/10.1016\/j.diabres.2019.107843","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"81585","doi-asserted-by":"crossref","unstructured":"Zanon E , Pasca S , Siragusa S , Napolitano M , Santoro C , Mameli L , et al.; FAIR Study Group . Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: data from the FAIR registry. Thromb Res. 2019 Feb;174:24\u20136. https:\/\/doi.org\/10.1016\/j.thromres.2018.12.006","DOI":"10.1016\/j.thromres.2018.12.006"},{"key":"81586","doi-asserted-by":"crossref","unstructured":"Baudo F , Collins P , Huth-K\u00fchne A , L\u00e9vesque H , Marco P , Nemes L , et al.; EACH2 registry contributors . Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012 Jul;120(1):39\u201346. https:\/\/doi.org\/10.1182\/blood-2012-02-408930","DOI":"10.1182\/blood-2012-02-408930"},{"key":"81587","doi-asserted-by":"crossref","unstructured":"Kruse-Jarres R , St-Louis J , Greist A , Shapiro A , Smith H , Chowdary P , et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 Mar;21(2):162\u201370. https:\/\/doi.org\/10.1111\/hae.12627","DOI":"10.1111\/hae.12627"},{"key":"81588","doi-asserted-by":"crossref","unstructured":"T\u00fcrkantoz H , K\u00f6nigs C , Kn\u00f6bl P , Klamroth R , Holstein K , Huth-K\u00fchne A , et al. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01\/2010 Study. J Thromb Haemost. 2020 Jan;18(1):36\u201343. https:\/\/doi.org\/10.1111\/jth.14618","DOI":"10.1111\/jth.14618"},{"key":"81589","doi-asserted-by":"crossref","unstructured":"Tiede A , Kemkes-Matthes B , Knobl P . Should Emicizumab Be Used in Patients with Acquired Haemophilia A? J Thromb Haemost. 2020.","DOI":"10.1111\/jth.15208"},{"key":"81590","doi-asserted-by":"crossref","unstructured":"Fontana P , Alberio L , Albisetti M , Angelillo-Scherrer A , Asmis LM , Casini A , et al. Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. Swiss Med Wkly. 2020 Dec;150(5153):w20422. https:\/\/doi.org\/10.4414\/smw.2020.20422","DOI":"10.4414\/smw.2020.20422"},{"key":"81591","doi-asserted-by":"crossref","unstructured":"Collins P , Baudo F , Knoebl P , L\u00e9vesque H , Nemes L , Pellegrini F , et al.; EACH2 registry collaborators . Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012 Jul;120(1):47\u201355. https:\/\/doi.org\/10.1182\/blood-2012-02-409185","DOI":"10.1182\/blood-2012-02-409185"},{"key":"81592","doi-asserted-by":"crossref","unstructured":"Dobbelstein C , Moschovakis GL , Tiede A . Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study. Ann Hematol. 2020 Sep;99(9):2105\u201312. https:\/\/doi.org\/10.1007\/s00277-020-04150-y","DOI":"10.1007\/s00277-020-04150-y"},{"key":"81593","doi-asserted-by":"crossref","unstructured":"Holstein K , Liu X , Smith A , Kn\u00f6bl P , Klamroth R , Geisen U , et al. Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study. Blood. 2020 Jul;136(3):279\u201387. https:\/\/doi.org\/10.1182\/blood.2019003639","DOI":"10.1182\/blood.2019003639"},{"key":"81594","doi-asserted-by":"crossref","unstructured":"Collins PW , Hirsch S , Baglin TP , Dolan G , Hanley J , Makris M , et al.; UK Haemophilia Centre Doctors\u2019 Organisation . Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation. Blood. 2007 Mar;109(5):1870\u20137. https:\/\/doi.org\/10.1182\/blood-2006-06-029850","DOI":"10.1182\/blood-2006-06-029850"},{"key":"81595","doi-asserted-by":"crossref","unstructured":"Knoebl P , Marco P , Baudo F , Collins P , Huth-K\u00fchne A , Nemes L , et al.; EACH2 Registry Contributors . Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012 Apr;10(4):622\u201331. https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04654.x","DOI":"10.1111\/j.1538-7836.2012.04654.x"},{"key":"81596","doi-asserted-by":"crossref","unstructured":"Borg JY , Guillet B , Le Cam-Duchez V , Goudemand J , L\u00e9vesque H , Group SS ; SACHA Study Group . Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l\u2019H\u00e9mophilie Acquise) registry. Haemophilia. 2013 Jul;19(4):564\u201370. https:\/\/doi.org\/10.1111\/hae.12138","DOI":"10.1111\/hae.12138"},{"key":"81597","doi-asserted-by":"crossref","unstructured":"Jayakar JP , O\u2019Neill N , Yan M , Nisenbaum R , Garvey MB , Teitel J , et al. Retrospective review of Acquired Haemophilia A from the largest Canadian Haemophilia treatment centre. Haemophilia. 2018 Sep;24(5):e383\u20137. https:\/\/doi.org\/10.1111\/hae.13598","DOI":"10.1111\/hae.13598"},{"key":"81598","doi-asserted-by":"crossref","unstructured":"Huang SY , Tsay W , Lin SY , Hsu SC , Hung MH , Shen MC . A study of 65 patients with acquired hemophilia A in Taiwan. J Formos Med Assoc. 2015 Apr;114(4):321\u20137. https:\/\/doi.org\/10.1016\/j.jfma.2013.01.006","DOI":"10.1016\/j.jfma.2013.01.006"}],"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/3309\/5623","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/3309\/5624","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/3309\/5623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T15:36:24Z","timestamp":1680536184000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/3309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.57187\/smw.2023.40048","relation":{},"ISSN":["1424-3997"],"issn-type":[{"value":"1424-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}